2021 AAN highlight impact and breadth of expanding neuroscience portfolio
The Pharma Data
APRIL 8, 2021
Roche will present data on the increased use of home nursing capabilities in the Phase III GRADUATE studies of gantenerumab during the COVID-19 pandemic, which enabled home-bound trial participants to continue dosing to maintain medicine exposure. At this time, EVRYSDI has been approved in 38 countries and submitted in a further 33 countries.
52 
Let's personalize your content